Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCAP-XX Regulatory News (CPX)

Share Price Information for CAP-XX (CPX)

Share Price is delayed by 15 minutes
Get Live Data
0.265    -0.005 (-1.85%)
Bid:
0.25
Ask:
0.28
Spread: 0.03 (12.00%)
Market Cap: £15.36m
CPX Live PriceLast checked at - London Stock Exchange

Intraday CAP-XX Share Chart

Trading update

20 Jun 2018 07:00

RNS Number : 9258R
CAP-XX Limited
20 June 2018
 

Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR).

 

20 June 2018

 

CAP-XX Limited

("CAP-XX" or "the Company")

Trading update

 

The Board of CAP-XX is pleased to announce that as it approaches the end of its financial year ending 30 June 2018, the Company has received a sharp increase in enquiry levels across all product ranges, including its recently announced 3 Volt technology. Total enquiries, if converted to orders, would amount to annualised sales in excess of US$20m per annum, including over US$2m which has already been classed as design wins, covering over 70 projects for cylindrical and automotive supercapacitors; small IoT and Thinline supercapacitors; and the new 3 Volt prismatic supercapacitors that are in development.

Following on from the announcement made in April 2018, the Company's new 3 Volt technology programme remains on track. As previously stated, the Board believes that the development of a 3 Volt prismatic supercapacitor will be a breakthrough for IoT applications using coin cell batteries. CAP-XX is currently commencing production trials and holding discussions with potential customers and licencees.

Royalty payments continue to grow strongly. Licensing activity remains a key focus, as CAP-XX negotiates new agreements and tackles intellectual property infringements. The Company expects to announce further progress in these respects shortly.

Revenues for the second half of the financial year ending 30 June 2018 are expected to be A$3.35m, including licence payments from AVX, which are significantly ahead of the first half of the year (first half total revenues: A$1.54m). These revenues are expected to result in a reduced EBITDA loss for the second half of the year of approximately A$120,000, compared to the first half EBITDA loss of A$1.5m.

The second half of the financial year includes revenues from the previously announced high volume order for prismatic cells, which has reduced the Company's average selling price by approximately 20%. This selling price reduction, together with the extra start-up costs for this production (as already reported); relocating manufacturing assets from a former contract manufacturer's site; and pursuing patent infringement actions, has reduced the Company's margins. For the financial year ending 30 June 2018, the Board therefore anticipates CAP-XX will generate total revenues of not less than A$4.9m and an EBITDA loss of A$1.6m. Closing cash is anticipated to be in excess of A$1.8m.

 

For further information contact:

 

CAP-XX Limited

Anthony Kongats (Chief Executive Officer) +61 (0) 2 9428 0139

Kreab (Financial PR)

Robert Speed +44 (0) 20 7074 1800

Allenby Capital (Nominated Adviser and Broker)

David Hart / Alex Brearley (Corporate Finance) +44 (0) 20 3328 5656

 

More information is available at www.cap-xx.com

 

Notes to Editors:

CAP-XX (LSE: CPX) is a world leader in the design and manufacture of thin, flat supercapacitors and energy management systems used in portable and small-scale electronic devices, and large supercapacitor based modules used in larger applications such as automotive and renewable energy. The unique feature of CAP-XX supercapacitors is their very high power density and high energy storage capacity in a space-efficient prismatic package. These attributes are essential in power-hungry consumer and industrial electronics, and deliver similar benefits in automotive and other transportation applications. For more information about CAP-XX, visit www.cap-xx.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTGGUBPQUPRPPB
Date   Source Headline
2nd Jul 20197:00 amRNSUS court action settlement and licence agreement
25th Jun 201910:45 amRNSIssue of Shares and Director/PDMR Shareholdings
7th Jun 20198:59 amRNSHolding(s) in Company
6th Jun 20199:03 amRNSTrading Update
30th May 20198:27 amRNSHolding(s) in Company
17th Apr 20193:09 pmRNSHolding(s) in Company
16th Apr 20197:00 amRNSTrading Update
6th Mar 20197:00 amRNSInterim Results
1st Mar 20197:36 amRNSDirector Disclosure Update
22nd Jan 20198:32 amRNSHolding(s) in Company
20th Dec 20188:43 amRNSIssue of Shares and Director/PDMR Shareholdings
20th Nov 20188:29 amRNSResult of AGM and Chairman's AGM statement
14th Nov 20187:00 amRNSHolding(s) in Company
5th Nov 20187:00 amRNSSubscription to raise £1.75 million
23rd Oct 20187:00 amRNSExercise of share options & PDMR shareholding
22nd Oct 201810:09 amRNSNotice of AGM
17th Oct 20187:00 amRNSAudited results for the year ended 30 June 2018
8th Oct 20182:05 pmRNSSecond Price Monitoring Extn
8th Oct 20182:00 pmRNSPrice Monitoring Extension
8th Oct 20187:00 amRNSNew licence agreement with TDK
5th Oct 20188:00 amRNSNotice of Results
25th Sep 201810:22 amRNSSpire Health Tags launched in Apple stores
18th Jul 20188:30 amRNSDirector/PDMR Shareholding
13th Jul 20187:00 amRNSExercise of share options
22nd Jun 20187:00 amRNSIssue of Shares and Director/PDMR Shareholdings
21st Jun 20187:00 amRNSExercise of share options & PDMR shareholding
20th Jun 20187:00 amRNSTrading update
1st May 20187:00 amRNSExercise of employee share options
11th Apr 20187:00 amRNSDeveloping first 3V thin prismatic supercapacitors
6th Mar 20182:25 pmRNSInterim Results (Replacement)
6th Mar 20187:00 amRNSInterim Results
15th Feb 20188:46 amRNSNotice of results
16th Jan 20187:00 amRNSHolding(s) in Company
18th Dec 201711:42 amRNSGrant of Share Options
12th Dec 201710:35 amRNSIssue of Shares and Director/PDMR Shareholdings
23rd Nov 20179:40 amRNSResult of AGM and Chairman's AGM statement
20th Nov 20177:00 amRNSSpire launches Thinline enabled wearable
30th Oct 20177:00 amRNSNotice of AGM
9th Oct 20177:00 amRNSAudited results for the year ended 30 June 2017
22nd Sep 20178:59 amRNSHolding(s) in Company
22nd Sep 20177:00 amRNSNotice of Results
23rd Aug 20178:37 amRNSHolding(s) in Company
15th Aug 20177:00 amRNSFirst high-volume order for Thinline
29th Jun 20178:22 amRNSIssue of Shares and Director/PDMR Shareholdings
7th Jun 20177:00 amRNSTrading update for year ending 30 June 2017
25th May 20178:51 amRNSExtension of option term and Director/PDMR dealing
19th Apr 20178:47 amRNSHolding(s) in Company
20th Mar 20177:00 amRNSInterim Results
9th Mar 20177:00 amRNSCAP-XX launches new cylindrical supercapacitors
1st Feb 20177:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.